Research Article

Berberine Inhibits Herpes Simplex Virus 1 Replication in HEK293T Cells

Yujuan Cui,1,2 Liangjun Zhang,2 Dandong Hu,1,2,3 and Yingli Yang1

1School of Life Science, Northwest Normal University, Lanzhou, Gansu 730070, China
2Beijing Yanqing Center for Diseases Prevention and Control, Beijing 102100, China
3Beijing Yanqing Market Supervision Inspection and Testing Monitoring Center, Beijing 102100, China

Correspondence should be addressed to Yingli Yang; 1450940233@xs.hnit.edu.cn

Received 23 August 2022; Accepted 29 September 2022; Published 14 October 2022

Copyright © 2022 Yujuan Cui et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Berberine exhibits polytrophic medicinal roles in various diseases and is safe and effective. However, its role and the underlying mechanism in the replication of herpes simplex virus 1 (HSV-1) remain unreported. This research aimed to determine the functional mechanisms of berberine on HSV-1 infection. We determined the CC50 (405.11 ± 15.67 μM) and IC50 (45.6 ± 6.84 μM) of berberine on HEK293T cells infected with HSV-1. Berberine inhibited the transcription and translation of HSV-1 activity-related genes (gD, ICP-4, ICP-5, and ICP-8) in HSV-1-infected HEK293T cells dose-dependently. Berberine also inhibited the phosphorylation of MAPK proteins (JNK and p38) and inflammatory responses induced by HSV-1 infection in HEK293T cells dose-dependently. In conclusion, berberine attenuates HSV-1 replication through its activity, infective ability, and inflammatory response. Our research indicated that berberine may be a candidate drug for HSV-1 infection.

1. Introduction

Herpes simplex virus (HSV) is a virus with double-stranded DNA under an envelope structure. HSV usually infects the body through the mucous membranes, skin, nerve tissue, and other related lesions. It has two serum subsets, HSV-1 and HSV-2. Infection with HSV-1 mainly leads to pharyngitis, cold sores, and keratitis and in severe cases will cause sporadic encephalitis and other dangerous diseases. HSV-2 mainly invades through damaged skin and mucous membranes to cause genital herpes [1]. Immediate early gene (α gene), early gene (β gene), and late gene (γ gene) express after HSV-1-infected host cells [2]. Infection cell protein (ICP4) expression peaks 2–4 hours after infection. The expression of the β gene requires activation of α gene products [3]. ICP5 and ICP8 can regulate viral DNA replication and participate in γ gene transcription [4]. Glycoprotein D (gD) is a late protein encoded by the γ gene peaking 12–15 hours after infection, which is the main component of the virus envelope and helps the virus to absorb and enter the host cell [5]. All these indicators can be used to evaluate the activity of HSV-1. Berberine is an alkaloid in the protoberberine group that existed in Berberidaceae, Papaveraceae, and Ranunculacea [6].

Berberine shows polytrophic medicinal effects, including anti-inflammatory [7], antibacterial, and antifungal [8]. Berberine acts on a series of signaling pathways to improve diabetes [9–11]. Several in vitro studies have found that berberine diminishes the proliferation, migration, and metastasis of cancer cells and accelerates apoptosis [11–13]. It has been found that berberine promotes apoptosis by activating ROS-related signals, such as the JNK/p38 signaling pathway. ROS can activate JNK/p38 that block antiapoptotic protein Bcl-XL expression to release cytochrome C and stimulate caspases [14]. Recently, berberine shows antiviral properties against influenza A virus (IAV) [15], respiratory syncytial virus (RSV) [16], chikungunya virus (CHIKV) [17], enterovirus 71 (EV71), [18], human papillomavirus (HPV) [19], and herpes simplex 55 virus (HSV) [20], but its roles in HSV-1 infection is still unknown.

Here, we aimed to explore the antiviral and anti-inflammatory impact of berberine in HSV-1-infected
HEK293T cells. It was reported that berberine can dose-dependently reduce the activity of HSV-1 and HSV-1-induced secretion of inflammatory factors and the phosphorylation of p38 and JNK.

2. Material and Methods

2.1. Material

2.1.1. Cells. HEK293T cells were obtained from Fudan University (Shanghai, China) and kept in DMEM (Roche, Basel, Switzerland) plus 1% antibiotics and 10% FBS (Solarbio, Beijing, China) under a humid incubator containing 5% CO₂ at 37°C.

2.1.2. Drugs and Cell Treatments. Berberine was purchased from Solarbio (Beijing, China, purity ≥98%). HEK293T cells were grouped: control group, cells were untreated; HSV group, infected with 200 pfu/well HSV; HSV+5 μM group, treated with 5 μM berberine and 200 pfu/well HSV; HSV+10 μM group, treated with 10 μM berberine and 200 pfu/well HSV; HSV+15 μM group, treated with 15 μM berberine and 200 pfu/well HSV. Following 24-h culture, HEK293T

Figure 1: Berberine antagonizes HSV-1 infection in HEK293T cells. (a) Berberine chemical structure. (b) CCK-8 assay was performed to explore berberine CC₅₀ in HEK293T cells. (c) Plaque reduction assay was carried out to explore berberine IC₅₀ in HEK293T cells. (d) Plaque reduction assay was performed to assess the effect of berberine on HSV-1 plaque formation in HEK293T cells. All data are presented as the means ± SD.
3. Methods

3.1. Cytotoxicity Assay. The cytotoxicity of berberine on HEK293T cells was determined based on the CCK-8 assay [21]. The minimum berberine concentration required to produce a toxic effect on 50% of HEK293T cells (CC50) was calculated by regression analysis of the dose-response curve.

3.2. Plaque Reduction Assay. The anti-HSV-1 ability of berberine was evaluated [21] (Jung et al., 2011). In detail, HEK293T cells (1 x 10^3/well) were cultured in a 24-well plate and treated with a corresponding dose of HSV-1 or berberine for 24 h. DMEM was added with 1% methylcellulose solution and 2% FCS (Solarbio, Beijing, China). Then, HEK293T cells were cultured under 5% CO2 at 37°C for 72 h. Monolayer cells were fixed and stained with 1% crystal violet, and formative plaques were counted. Finally, the minimum berberine concentration required to inhibit the 50% cytopathic effect (IC50) was calculated by regression analysis of the dose-response curve. The selectivity index (SI) was calculated by CC50/IC50.

3.3. RT-qPCR. RNA was isolated using TRIzol (Takara, Liao- ning, China), and cDNA was obtained with M-MLV Reverse Transcriptase (RNase H) kit (Takara, Liaoning, China). RT-qPCR was performed according to the previous report [22].

3.4. ELISA. Following treatment with corresponding doses of HSV-1 or berberine for 24 h, 1 mL of extraction solution (Beyotime, Nanjing, China) was used to lyse HEK293T cells. Subsequently, the levels of inflammatory factors in the supernatant were determined with ELISA kits (Roche, Basel, Switzerland).

Figure 2: Berberine decreases HSV-1 activity in HEK293T cells. (a) RT-qPCR was performed to assess the mRNA levels of HSV-1-related genes, including gD, ICP4, ICP5, and ICP8. All data are presented as the means ± SD. **P < 0.01 vs. control group, #P < 0.05 vs. HSV group, ΔP < 0.05 vs. HSV+5 μM group, and +P < 0.05 vs. HSV+10 μM group. (b) Western blot was performed to measure the protein levels of gD, ICP4, ICP5, and ICP8.
4. Results

4.1. Berberine Antagonizes HSV-1 Infection in HEK293T Cells. Berberine’s chemical structure formula was analyzed (Figure 1(a)), and CCK-8 assay was conducted to explore berberine cytotoxicity on HEK293T cells. The CC$_{50}$ of berberine on HEK293T cells was calculated to be 405.11 ± 15.67 μM, according to the regression analysis of the dose-response curve generated by CCK-8 assay (Figure 1(b)). In Figure 1(c), the IC$_{50}$ of berberine on HEK293T cell infected with HSV-1 was 45.6 ± 6.84 μM based on plaque reduction assay. The decrease in HSV-1 plaque formation caused by the increase in berberine concentration was dose-related, indicating that berberine could inhibit HSV-1 infection of HEK293T cells. The selective index (SI) was 7.43-10.86 (in Figure 1(d)).

4.2. Berberine Decreases HSV-1 Activity in HEK293T Cells. To further analyze the effects of berberine on HSV-1 activity in HEK293T cells, RT-qPCR and western blot analyses were followed to assess the levels of HSV-1 infection-related genes, including g D, ICP-4, ICP-5, and ICP-8. RT-qPCR manifested that HSV-1 upregulated the transcription of the four HSV-1 infection-related genes, relative to the control group (P < 0.01), while berberine antagonized this upregulation effect dose-dependently compared with the HSV group (Figure 2(a); P < 0.05). Consistently, HSV infection promoted g D, ICP-4, ICP-5, and ICP-8 protein expression, whereas berberine antagonized this promotion dose-dependently (Figure 2(b); P < 0.05). Taken together, berberine deceased HSV-1 activity in HEK293T cells.

4.3. Berberine Inhibits JNK and p38 Activation Induced by HSV-1 Infection. It has been revealed that HSV-1 activated the MAPK pathway [24, 25]. To further explore the effect of HSV-1 on the MAPK pathway, the phosphorylation levels of MAPK-related proteins (JNK and p38) in HEK293T cells were assessed. Results showed that HSV-1 infection upregulated the phosphorylation levels of JNK (P < 0.01) and p38 (P < 0.001) proteins. Besides, further investigation indicated that berberine inhibited the HSV-1 infection-induced phosphorylation levels of JNK and p38 in HEK293T cells dose-dependently (P < 0.05; Figure 3). Collectively, berberine inhibited JNK and p38 activation in HSV-1-treated HEK293T cells.

4.4. Berberine Decreases Inflammatory Responses Induced by HSV-1 Infection. HSV-1 triggers inflammatory responses, such as gingival stomatitis, cold sores, keratitis, and meningitis [26, 27]. To investigate the effect of berberine on inflammatory responses caused by HSV-1, RT-qPCR and ELISA were conducted. Our results showed that HSV-1 infection upregulated the mRNA and secretion levels of cytokines (P < 0.05) and berberine dose-dependently...
downregulated their levels triggered by HSV-1 infection ($P < 0.05$; Figures 4(a) and 4(b)). Taken together, berberine inhibited inflammatory responses induced by HSV-1 infection in HEK293T cells.

5. Discussion

Herpesviruses develop latency or cause oral and genital herpes, conjunctivitis, eczema herpeticum, and other diseases in 90% of the population. Herpesvirus also disturbs AIDS treatment under HIV infection [28]. It is important to seek drug candidates against HSV-1. Here, it was proved that berberine antagonized HSV-1 activity, inflammatory responses, and MAPK pathway activation in HEK293T cells which may contribute to the inhibition of HSV-1.

Berberine is cytotoxic to mast cells, rat hepatocytes, and Vero cells [17, 29, 30]. Cytotoxicity is a factor that must be considered in seeking a candidate for HSV-1 treatment. A study showed that berberine exerted an anticancer impact against HeLa cells with $CC_{50}$ of 12.08 $\mu$g/mL whereas
exhibited low toxicity (CC_{50}: 71.14 μg/mL) on normal Vero cells [31]. Chin et al. found that the CC_{50} of berberine extracted from Coptis chinensis on Vero cells was 392.5 μM, the IC_{50} was 66.49 μM, and the SI was 5.9 [32]. Our results found that berberine could effectively inhibit HSV-1 activity (IC_{50}: 45.6 ± 6.84 μM) in HEK293T cells and was with low toxicity (CC_{50}: 405.11 ± 15.67 μM). The SI was 7.43-10.86, indicating berberine is a relatively safe and effective candidate for HSV-1 inhibition in vitro.

Our study found that HSV-1 infection upregulates the phosphorylation levels of JNK and p38 proteins, which was similar to other’s reports. MAPK pathway activation was stimulated by HSV-1 infection [24, 25]. Berberine was illustrated to reduce the phosphorylation levels of JNK and p38 MAPK under CVB3 infection [33]. Zeng et al. illuminated the mechanism of berberine weakened host components JNK-MAPK, ERK-MAPK, and p38-MAPK activation [34]. Li et al. found that berberine retarded IL-33-stimulated cytokine production in RPMCs [29]. It has been demonstrated that the levels of ROS-related factors were boosted under IL-1β treatment and pretreatment of berberine exhibited inhibitory roles. Besides, the decrease in inflammatory responses indicated that berberine diminished the HSV-1 infection-caused inflammation.

In conclusion, our study showed that berberine inhibited HSV-1 replication by downregulation of HSV-1 activity, inflammatory responses, and MAPK pathway activation in HEK293T cells. Berberine may be a potential candidate for the treatment of HSV-1 infection.

**Data Availability**

The data supporting the manuscript’s conclusions will be made available to any qualified researcher without reservation.

**Conflicts of Interest**

There are no conflicts of interest to declare.

**References**

[1] A. J. Debono, S. J. Mistry, J. Xie et al., “The synthesis and biological evaluation of multifunctionalised derivatives of noscapine as cytotoxic agents,” ChemMedChem, vol. 9, no. 2, pp. 399–410, 2014.

[2] J. L. Coleman and D. Shukla, “Recent advances in vaccine development for herpes simplex virus types I and II,” Human Vaccines & Immunotherapeutics, vol. 9, no. 4, pp. 729–735, 2013.

[3] D. Chen, A. Su, Y. Fu et al., “Harmane blocks herpes simplex virus infection through downregulating cellular NF-kB and MAPK pathways induced by oxidative stress,” Antiviral Research, vol. 123, pp. 27–38, 2015.

[4] K. F. Bryant, Z. Yan, D. H. Dreyfus, and D. M. Knipe, “Identification of a divergent metal cation binding site in herpes simplex virus 1 (HSV-1) ICP8 required for HSV replication,” Journal of Virology, vol. 86, no. 12, pp. 6825–6834, 2012.

[5] R. I. Montgomery, M. S. Warner, B. J. Lum, and P. G. Spear, “Herpes simplex virus-1 entry into cells mediated by a novel member of the TNF/NGF receptor family,” Cell, vol. 87, no. 3, pp. 427–436, 1996.

[6] H. Mortazavi, B. Nikfar, S. A. Esmaeili et al., “Potential cytotoxic and anti-metastatic effects of berberine on gynaecological cancers with drug-associated resistance,” European Journal of Medicinal Chemistry, vol. 187, article 111951, 2020.

[7] E. Küpeli, M. Koşar, E. Yesilada, K. Hüsnü, and C. Başer, “A comparative study on the anti-inflammatory, antinociceptive and antipyretic effects of isouquinoline alkaloids from the roots of Turkish Berberis species,” Life Sciences, vol. 72, no. 6, pp. 645–657, 2002.

[8] A. H. Amin, T. V. Subbaiah, and K. M. Abbasi, “Berberine sulfate: antimicrobial activity, bioassay, and mode of action,” Canadian Journal of Microbiology, vol. 15, no. 9, pp. 1067–1076, 1969.

[9] Q. Chen, R. Mo, N. Wu et al., “Berberine ameliorates diabetes-associated cognitive decline through modulation of aberrant inflammation response and insulin signaling pathway in DM rats,” Frontiers in Pharmacology, vol. 8, p. 334, 2017.

[10] L. Zhu, J. Han, R. Yuan, L. Xue, and W. Pang, “Berberine ameliorates diabetic nephropathy by inhibiting TLR4/NF-κB pathway,” Biological Research, vol. 51, no. 1, p. 9, 2018.

[11] X. Zhang, L. Gu, J. Li et al., “Degradation of MDM2 by the interaction between berberine and DAXX leads to potent apoptosis in MDM2-overexpressing cancer cells,” Cancer Research, vol. 70, no. 23, pp. 9895–9904, 2010.

[12] J. Li, L. Gu, H. Zhang et al., “Berberine represses DAXX gene transcription and induces cancer cell apoptosis,” Laboratory Investigation; A Journal of Technical Methods and Pathology, vol. 93, no. 3, pp. 354–364, 2013.

[13] Y. Wang and S. Zhang, “Berberine suppresses growth and metastasis of endometrial cancer cells via miR-101/COX-2,” Biomedicine & Pharmacotherapy = Biomedecine & Pharma-cotherapie, vol. 103, pp. 1287–1293, 2018.

[14] Y. H. Kang, E. Lee, M. K. Choi et al., “Role of reactive oxygen species in the induction of apoptosis by alpha-tocopheryl succinate,” International Journal of Cancer, vol. 112, no. 3, pp. 385–392, 2004.

[15] Y. Wu, J. Q. Li, Y. J. Kim, J. Wu, Q. Wang, and Y. Hao, “In vivo and in vitro antiviral effects of berberine on influenza virus,” Chinese Journal of Integrative Medicine, vol. 17, no. 6, pp. 444–452, 2011.

[16] H. B. Shin, M. S. Choi, C. M. Yi, J. Lee, N. J. Kim, and K. S. Inn, “Inhibition of respiratory syncytial virus replication and virus-induced p38 kinase activity by berberine,” International Immunopharmacology, vol. 27, no. 1, pp. 65–68, 2015.

[17] F. S. Varghese, B. Thaa, S. N. Amrun et al., “The antiviral alkalo- id berberine reduces chikungunya virus-induced mitogen-activated protein kinase signaling,” Journal of Virology, vol. 90, no. 21, pp. 9743–9757, 2016.

[18] H. Wang, K. Li, L. Ma et al., “Berberine inhibits enterovirus 71 replication by downregulating the MEK/ERK signaling pathway and autophagy,” Viruses Journal, vol. 14, no. 1, p. 2, 2017.

[19] S. Mahata, A. C. Bharti, S. Shukla, A. Tyagi, S. A. Husain, and B. C. Das, “Berberine modulates AP-1 activity to suppress HPV transcription and downstream signaling to induce growth arrest and apoptosis in cervical cancer cells,” Molecular Cancer, vol. 10, no. 1, p. 39, 2011.

[20] S. Song, M. Qiu, Y. Chu et al., “Downregulation of cellular c-Jun N-terminal protein kinase and NF-κB activation by berberine may result in inhibition of herpes simplex virus
replication,” *Antimicrobial Agents and Chemotherapy*, vol. 58, no. 9, pp. 5068–5078, 2014.

[21] J. S. Chang, K. C. Wang, D. E. Shieh, and L. C. Chiang, “Liu-He-Tang inhibited plaque formation by human respiratory syncytial virus infection in cell lines of the human respiratory tract,” *Journal of Ethnopharmacology*, vol. 137, no. 3, pp. 1149–1155, 2011.

[22] S. M. Dong, J. H. Cui, W. Zhang et al., “Inhibition of translation initiation factor eIF4A is required for apoptosis mediated by Microplitis bicoloratus bracovirus,” *Archives of Insect Biochemistry and Physiology*, vol. 96, no. 3, article e21423, 2017.

[23] K. Nakai, S. Karita, J. Igarashi, I. Tsukamoto, K. Hirano, and Y. Kubota, “COA-Cl prevented TGF-β1-induced CTGF expression by Akt dephosphorylation in normal human dermal fibroblasts, and it attenuated skin fibrosis in mice models of systemic sclerosis,” *Journal of Dermatological Science*, vol. 94, no. 1, pp. 205–212, 2019.

[24] M. Watanabe, J. Arii, K. Takeshima et al., “Prohibitin-1 contributes to cell-to-cell transmission of herpes simplex virus 1 via the MAPK/ERK signaling pathway,” *Journal of Virology*, vol. 95, no. 3, 2021.

[25] I. Sufiawati and S. M. Tugizov, “HIV-induced matrix metalloproteinase-9 activation through mitogen-activated protein kinase signalling promotes HSV-1 cell-to-cell spread in oral epithelial cells,” *The Journal of General Virology*, vol. 99, no. 7, pp. 937–947, 2018.

[26] N. R. Dhanushkodi, R. Srivastava, S. Prakash et al., “High frequency of gamma interferon-producing PLZF-LORORO variant natural killer 1 cells infiltrating herpes simplex virus 1-infected corneas is associated with asymptomatic ocular herpesvirus infection,” *Journal of Virology*, vol. 94, no. 9, 2020.

[27] K. Tormanen, S. Wang, and H. Ghiasi, “CD80 plays a critical role in increased inflammatory responses in herpes simplex virus 1-infected mouse corneas,” *Journal of Virology*, vol. 94, no. 2, 2020.

[28] M. K. Kukhanova, A. N. Korovina, and S. N. Kochetkov, “Human herpes simplex virus: life cycle and development of inhibitors,” *Biochemistry Biokhimiia*, vol. 79, no. 13, pp. 1635–1652, 2014.

[29] W. Li, N. Yin, W. Tao, Q. Wang, H. Fan, and Z. Wang, “Berberine suppresses IL-33-induced inflammatory responses in mast cells by inactivating NF-κB and p38 signaling,” *International Immunopharmacology*, vol. 66, pp. 82–90, 2019.

[30] L. Gao, H. J. Schmitz, K. H. Merz, and D. Schrenk, “Characterization of the cytotoxicity of selected _Chelidonium_ alkaloids in rat hepatocytes,” *Toxicology Letters*, vol. 311, pp. 91–97, 2019.

[31] A. Belanova, D. Beseda, V. Chmykhalo et al., “Berberine effects on NFκB, HIF1α and NFE2L2/AP-1 pathways in HeLa cells,” *Anti-Cancer Agents in Medicinal Chemistry*, vol. 19, no. 4, pp. 487–501, 2019.

[32] L. W. Chin, Y. W. Cheng, S. S. Lin et al., “Anti-herpes simplex virus effects of berberine from Coptidis rhizoma, a major component of a Chinese herbal medicine, *Ching-Wei-San,*” *Archives of Virology*, vol. 155, no. 12, pp. 1933–1941, 2010.

[33] Q. Dai, D. Zhang, H. Yu et al., “Berberine restricts coxsackievirus B type 3 replication via inhibition of c-Jun N-terminal kinase (JNK) and p38 MAPK activation in vitro,” *Medical Science Monitor*, vol. 23, pp. 1448–1455, 2017.

[34] Q. X. Zeng, H. Q. Wang, W. Wei et al., “Synthesis and biological evaluation of berberine derivatives as a new class of broad-spectrum antiviral agents against coxsackievirus B,” *Bioorganic Chemistry*, vol. 95, article 103490, 2020.